HN2010002786A - Compuestoa quimicos 251 - Google Patents
Compuestoa quimicos 251Info
- Publication number
- HN2010002786A HN2010002786A HN2010002786A HN2010002786A HN2010002786A HN 2010002786 A HN2010002786 A HN 2010002786A HN 2010002786 A HN2010002786 A HN 2010002786A HN 2010002786 A HN2010002786 A HN 2010002786A HN 2010002786 A HN2010002786 A HN 2010002786A
- Authority
- HN
- Honduras
- Prior art keywords
- pim
- invention refers
- kinase
- chemical composite
- preferibly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS QUIMICOS I Y SALES DE LOS MISMOS. EN ALGUNAS REALIZACIONES, LA INVENCION SE REFIERE A INHIBIDORES O MODULADORES DE LA ACTIVIDAD O FUNCION ENZIMATICA DE LA QUINASA PIM-1 Y/O PIM-2 Y/O PIM-3. EN OTRAS REALIZACIONES ADICIONALES, LA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN COMPUESTOS DESCRITOS EN LA PRESENTE Y SU USO EN LA PREVENCION Y TRATMIENTO DE AFECCIONES Y ENFERMEDADES RELACIONADAS CON LA QUINASA PIM, PREFERIBLEMENTE CANCER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7763908P | 2008-07-02 | 2008-07-02 | |
US18327809P | 2009-06-02 | 2009-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2010002786A true HN2010002786A (es) | 2013-01-28 |
Family
ID=41050276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2010002786A HN2010002786A (es) | 2008-07-02 | 2010-12-30 | Compuestoa quimicos 251 |
Country Status (27)
Country | Link |
---|---|
US (2) | US8901307B2 (es) |
EP (1) | EP2310010A2 (es) |
JP (2) | JP5261575B2 (es) |
KR (1) | KR20110031367A (es) |
CN (2) | CN102137666B (es) |
AR (1) | AR072791A1 (es) |
AU (1) | AU2009265362B2 (es) |
BR (1) | BRPI0914599A2 (es) |
CA (1) | CA2729557A1 (es) |
CL (1) | CL2010001636A1 (es) |
CO (1) | CO6341555A2 (es) |
CR (1) | CR20110016A (es) |
DO (1) | DOP2010000408A (es) |
EA (1) | EA018989B1 (es) |
EC (1) | ECSP10010735A (es) |
HN (1) | HN2010002786A (es) |
IL (1) | IL210127A0 (es) |
MX (1) | MX2010014233A (es) |
MY (1) | MY155961A (es) |
NI (1) | NI201100007A (es) |
NZ (1) | NZ590859A (es) |
PE (1) | PE20120304A1 (es) |
SV (1) | SV2011003786A (es) |
TW (1) | TWI461423B (es) |
UY (1) | UY31952A (es) |
WO (1) | WO2010001169A2 (es) |
ZA (1) | ZA201100844B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
CA2689663C (en) | 2007-06-13 | 2016-08-09 | Incyte Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
UY31952A (es) * | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
KR20220015492A (ko) | 2010-03-10 | 2022-02-08 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
PL2574168T3 (pl) | 2010-05-21 | 2016-10-31 | Preparaty inhibitora kinazy janusowej do stosowania miejscowego | |
CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
EP2721028B1 (en) | 2011-06-20 | 2015-11-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013051672A1 (ja) * | 2011-10-04 | 2013-04-11 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とする医薬品 |
US9422246B2 (en) | 2012-03-30 | 2016-08-23 | Rohto Pharmaceutical Co., Ltd. | Benzylidene azolidine derivative or salt thereof |
WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
PE20200175A1 (es) | 2012-11-15 | 2020-01-24 | Incyte Holdings Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
BR122019024759B1 (pt) | 2013-01-15 | 2022-02-08 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
UA120162C2 (uk) | 2013-03-06 | 2019-10-25 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки при отриманні інгібітора jak |
JP6378918B2 (ja) * | 2013-04-03 | 2018-08-22 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とするPim阻害剤 |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
CA3155500A1 (en) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
MX2016002367A (es) | 2013-08-23 | 2016-10-28 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. |
JP5799148B2 (ja) * | 2013-09-27 | 2015-10-21 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
TW201601763A (zh) * | 2013-09-27 | 2016-01-16 | 樂敦製藥股份有限公司 | 皮膚外用組成物 |
JPWO2015122504A1 (ja) * | 2014-02-13 | 2017-03-30 | 国立大学法人 東京大学 | キナーゼ阻害剤 |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
JP5857104B2 (ja) * | 2014-06-17 | 2016-02-10 | ロート製薬株式会社 | ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US10195189B2 (en) | 2014-12-15 | 2019-02-05 | Prosetta Antiviral, Inc. | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds |
CN105985298B (zh) * | 2015-02-10 | 2018-02-23 | 湖南大学 | 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
RU2736045C2 (ru) | 2015-03-06 | 2020-11-11 | Бейондспринг Фармасьютикалс, Инк. | Способ лечения рака, ассоциированного с мутацией ras |
CN106032365B (zh) * | 2015-03-11 | 2018-03-23 | 湖南大学 | 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
AU2017217426B2 (en) | 2016-02-08 | 2022-12-01 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
EP3439667B1 (en) * | 2016-04-05 | 2024-01-03 | Immune Sensor, LLC | Cgas antagonist compounds |
BR112018074990A2 (pt) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composição, usos e método para reduzir neutropenia |
MX2018015483A (es) | 2016-06-13 | 2019-03-18 | Glaxosmithkline Ip Dev Ltd | Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1). |
CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
CN112739345A (zh) | 2017-11-06 | 2021-04-30 | 斯奈普生物公司 | Pim激酶抑制剂组合物,方法和其用途 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
EP3743074A4 (en) | 2018-01-24 | 2021-12-15 | Beyondspring Pharmaceuticals Inc. | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE |
CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
JP7491510B2 (ja) * | 2018-04-26 | 2024-05-28 | メディシナル バイオコンバージェンス リサーチ センター | mTOR阻害剤としての新規化合物及びその用途 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
CN116354901B (zh) * | 2023-04-12 | 2024-04-26 | 郑州大学 | 一种噻唑烷二酮类化合物及其制备方法和应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE62214B1 (en) * | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
CA2146701A1 (en) * | 1994-04-11 | 1995-10-12 | Takashi Fujita | Heterocyclic compounds having anti-diabetic activity, their preparation and their use |
JP3668291B2 (ja) * | 1995-06-16 | 2005-07-06 | 久光製薬株式会社 | 新規なピペリジン誘導体 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
TW577875B (en) * | 1997-01-31 | 2004-03-01 | Shionogi & Co | Pyrrolidine derivatives with inhibitory activity for phospholipase A2 |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
ID29875A (id) * | 1999-07-01 | 2001-10-18 | Geron Corp Cs | Penghambat-penghambat telomerase dan metode penggunaannya |
TW593293B (en) * | 1999-08-23 | 2004-06-21 | Kyorin Seiyaku Kk | Substituted benzylthiazolidine-2,4-dione derivatives |
US6730687B1 (en) * | 1999-08-23 | 2004-05-04 | Kyorin Pharmaceutical Co., Ltd. | Substituted benzylthiazolidine-2, 4-dione derivatives |
AU1595001A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
US6452014B1 (en) * | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
BR0312650A (pt) | 2002-07-10 | 2005-05-03 | Applied Research Systems | Derivados de benzeno fundido azolidinona-vinila |
JP2006523724A (ja) * | 2003-04-18 | 2006-10-19 | インサイト サン ディエゴ インコーポレイテッド | 代謝障害、癌および他の疾患の治療のための置換イソクロマン化合物 |
EP1751133B1 (en) * | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
US7714005B2 (en) * | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
WO2009064486A2 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
UY31952A (es) * | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
-
2009
- 2009-07-01 UY UY0001031952A patent/UY31952A/es not_active Application Discontinuation
- 2009-07-01 TW TW098122261A patent/TWI461423B/zh not_active IP Right Cessation
- 2009-07-02 JP JP2011515631A patent/JP5261575B2/ja not_active Expired - Fee Related
- 2009-07-02 EA EA201100119A patent/EA018989B1/ru not_active IP Right Cessation
- 2009-07-02 AR ARP090102486A patent/AR072791A1/es unknown
- 2009-07-02 CN CN200980134849.5A patent/CN102137666B/zh not_active Expired - Fee Related
- 2009-07-02 US US13/000,138 patent/US8901307B2/en not_active Expired - Fee Related
- 2009-07-02 WO PCT/GB2009/050773 patent/WO2010001169A2/en active Application Filing
- 2009-07-02 PE PE2010001221A patent/PE20120304A1/es not_active Application Discontinuation
- 2009-07-02 MY MYPI2010006322A patent/MY155961A/en unknown
- 2009-07-02 NZ NZ590859A patent/NZ590859A/xx not_active IP Right Cessation
- 2009-07-02 EP EP09772849A patent/EP2310010A2/en not_active Withdrawn
- 2009-07-02 BR BRPI0914599A patent/BRPI0914599A2/pt not_active IP Right Cessation
- 2009-07-02 MX MX2010014233A patent/MX2010014233A/es active IP Right Grant
- 2009-07-02 AU AU2009265362A patent/AU2009265362B2/en not_active Ceased
- 2009-07-02 CN CN201410037508.9A patent/CN103804371A/zh active Pending
- 2009-07-02 KR KR1020117002754A patent/KR20110031367A/ko not_active Application Discontinuation
- 2009-07-02 CA CA2729557A patent/CA2729557A1/en not_active Abandoned
-
2010
- 2010-12-20 IL IL210127A patent/IL210127A0/en unknown
- 2010-12-30 DO DO2010000408A patent/DOP2010000408A/es unknown
- 2010-12-30 EC EC2010010735A patent/ECSP10010735A/es unknown
- 2010-12-30 CL CL2010001636A patent/CL2010001636A1/es unknown
- 2010-12-30 HN HN2010002786A patent/HN2010002786A/es unknown
-
2011
- 2011-01-03 SV SV2011003786A patent/SV2011003786A/es unknown
- 2011-01-05 NI NI201100007A patent/NI201100007A/es unknown
- 2011-01-10 CR CR20110016A patent/CR20110016A/es unknown
- 2011-02-01 CO CO11011427A patent/CO6341555A2/es active IP Right Grant
- 2011-02-01 ZA ZA2011/00844A patent/ZA201100844B/en unknown
-
2013
- 2013-02-20 JP JP2013031176A patent/JP2013139459A/ja not_active Ceased
-
2014
- 2014-07-24 US US14/339,981 patent/US20150051185A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2010002786A (es) | Compuestoa quimicos 251 | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
BRPI0712816B8 (pt) | compostos de pirrolpirimidina e seus usos | |
AU2011338389A8 (en) | Bicyclic compounds as Pim inhibitors | |
CL2010001368A1 (es) | Compuestos derivados de 1,3-tiazina; composicion farmaceutica que lo comprende; utiles para inhibir a la beta-secretasa | |
BRPI0815708A8 (pt) | composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto | |
BR112015007083A2 (pt) | inibidores de histona demetilases | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
CR9949A (es) | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) | |
ECSP10010310A (es) | Nuevos compuestos y composiciones y métodos de uso | |
GT200500137A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis. | |
UY30578A1 (es) | Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones | |
SV2010003706A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
ECSP088152A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
GT200900027A (es) | Compuestos organicos | |
UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
UY30220A1 (es) | Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo | |
MX2013012661A (es) | Compuestos de piridazina biciclicos como inhibidores pim. | |
GT200800206A (es) | Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica | |
ECSP088252A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
UY29417A1 (es) | Agentes endoparasiticidas | |
CR10524A (es) | Compuesto triciclico y uso farmaceutico del mismo | |
HN2011000404A (es) | Derivados de enfumafungina y composicion comprendiendo los mismos | |
CR11665A (es) | Farmacoforos duales-antagonistas muscarinicos de pde4 |